E-Learning

On Wednesday, the FDA approved Mesoblast Limited’s (NASDAQ:MESO) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy approved in the U.S. for any indication and the only therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents. Ryoncil contains MSCs, a type of cell that can have various roles in the body and can differentiate into multiple other types of cell

Canoo Inc. (NASDAQ:GOEV) shares are trading lower in the premarket session on Thursday. The company is grappling with major financial challenges, leading to the furlough of 82 employees and the temporary shutdown of its factories in Oklahoma. The move comes as the electric vehicle manufacturer works to secure the necessary capital to continue its operations. Canoo is currently in advanced discussions with multiple capital sources but acknowledges the tough decision to furlough staff, particularl

Looking for the best money market account interest rates available today? Here’s a look at where to find the highest rates and whether now is a good time to open a money market account.

Stock investing ultimately revolves around generating returns. Achieving this goal requires building a strategically curated portfolio focused on value creation. While growth stocks often take center stage, incorporating high-yield dividend stocks can provide stability and bolster overall performance. Reliable dividends ensure a regular income stream, and high yields can beat the prevailing interest rates. While dividend stocks are usually considered a defensive stance, the best of these income-

The S&P 500 suffered its biggest post-Fed decision slide on record Wednesday.

PizzaExpress is partnering with franchising group Purple Square for the expansion.

This marks a return to the kiosk space for Coen, which previously offered self-checkout technology via now-defunct checkout tech company Grabango.

Some on Wall Street see artificial intelligence-driven demand poised to push sales of Broadcom's chips to fresh highs, powering its stock higher in 2025. But others are more cautious—in the near term, at least.

(Bloomberg) -- After falling off their perch in the last few months of 2024, European healthcare stocks head into a new year facing the jeopardy of US politics and high-stakes trial results for new drugs.Most Read from BloombergNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalKey for investors will be clarity on American healthcare policy after president-elect Donald Trump’s nomination of health officials, including a

A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.